Adaptimmune Therapeutics Plc - ADR

NASDAQ:ADAP   3:59:51 PM EDT
1.63
-0.04 (-2.40%)
Earnings Announcements

Adaptimmune Reports First Quarter Financial Results

Published: 05/09/2022 13:46 GMT
Adaptimmune Therapeutics Plc - ADR (ADAP) - Adaptimmune Reports First Quarter Financial Results and Business Update.
Revenue for Three Months Ended March 31, 2022 Was $3.6 Million, Compared to $0.4 Million for Same Period in 2021.
Qtrly Loss per Share $0.05.
As of March 31, 2022, Adaptimmune Had Cash and Cash Equivalents of $89.5 Million.
Q1 Earnings per Share View $-0.22, Revenue View $3.3 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $6.57 Million
Adjusted EPS is expected to be -$0.29

Next Quarter Revenue Guidance is expected to be $6.3 Million
Next Quarter EPS Guidance is expected to be -$0.31

More details on our Analysts Page.